Press Enter to search · ESC to close

Regulation

China NMPA Moves to Optimize Review of Chemical APIs and Cell & Gene Therapies

China’s National Medical Products Administration (NMPA) held a meeting chaired by Director Huang Guo to optimize the management of chemical active pharmaceutical ingredients and the review and approval of cell and gene therapy drugs. The meeting reviewed and approved the Provisions on the Administration of Changes to Registration Holders of Chemical APIs and the Announcement on Matters Concerning the Optimization of Review and Approval of Cell and Gene Therapy Drugs.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback